X4 Pharmaceuticals (XFOR) Non-Current Debt (2017 - 2025)
X4 Pharmaceuticals (XFOR) posted Non-Current Debt of $75.0 million for Q4 2025, down 1.4% on a QoQ basis from $76.1 million in Q3 2025, and down 0.56% year-over-year from $75.4 million in Q4 2024.
X4 Pharmaceuticals (XFOR) Non-Current Debt (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals' Non-Current Debt history runs 9 years deep, the most recent figure standing at $75.0 million for Q4 2025.
- Quarterly Non-Current Debt fell 0.56% year-over-year to $75.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $75.0 million (down 0.56% YoY) and the FY2025 annual result came in at $75.0 million, down 0.56% from the prior year.
- Non-Current Debt was $75.0 million for Q4 2025 at X4 Pharmaceuticals, down from $76.1 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $76.1 million in Q3 2025 and bottomed at $29.8 million in Q1 2022.
- A 5-year average of $50.7 million and a median of $43.8 million in 2021 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt decreased 10.63% — and 2024, when it surged 135.58%.
- X4 Pharmaceuticals' Non-Current Debt stood at $32.5 million in 2021, then changed by 0.0% to $32.5 million in 2022, then jumped by 67.91% to $54.6 million in 2023, then soared by 38.22% to $75.4 million in 2024, then declined by 0.56% to $75.0 million in 2025.
- Business Quant data shows XFOR's Non-Current Debt at $75.0 million in Q4 2025, $76.1 million in Q3 2025, and $75.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 105.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 842.92 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn | 75.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 75.00 Mn |
| Sep 30, 2025 | 76.06 Mn |
| Jun 30, 2025 | 75.00 Mn |
| Mar 31, 2025 | 75.63 Mn |
| Dec 31, 2024 | 75.43 Mn |
| Sep 30, 2024 | 75.22 Mn |
| Jun 30, 2024 | 75.00 Mn |
| Mar 31, 2024 | 54.82 Mn |
| Dec 31, 2023 | 54.57 Mn |
| Sep 30, 2023 | 54.32 Mn |
| Jun 30, 2023 | 31.84 Mn |
| Mar 31, 2023 | 31.83 Mn |
| Dec 31, 2022 | 32.50 Mn |
| Sep 30, 2022 | 32.50 Mn |
| Jun 30, 2022 | 32.50 Mn |
| Mar 31, 2022 | 29.81 Mn |
| Dec 31, 2021 | 32.50 Mn |
| Sep 30, 2021 | 33.04 Mn |
| Jun 30, 2021 | 32.50 Mn |
| Mar 31, 2021 | 33.36 Mn |